-
Je něco špatně v tomto záznamu ?
Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry
TC. Godschalk, RA. Byrne, T. Adriaenssens, N. Malik, LJ. Feldman, G. Guagliumi, F. Alfonso, FJ. Neumann, D. Trenk, M. Joner, C. Schulz, PG. Steg, AH. Goodall, R. Wojdyla, D. Dudek, JJ. Wykrzykowska, O. Hlinomaz, AG. Zaman, N. Curzen, J. Dens, P....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem
- MeSH
- adenosindifosfát krev MeSH
- antagonisté purinergních receptorů P2Y škodlivé účinky terapeutické užití MeSH
- biologické markery krev MeSH
- časové faktory MeSH
- infarkt myokardu s elevacemi ST úseků krev diagnostické zobrazování etiologie chirurgie MeSH
- inhibitory agregace trombocytů škodlivé účinky terapeutické užití MeSH
- koronární angioplastika škodlivé účinky přístrojové vybavení MeSH
- koronární trombóza krev diagnostické zobrazování etiologie prevence a kontrola MeSH
- léková rezistence MeSH
- lidé středního věku MeSH
- lidé MeSH
- purinergní receptory P2Y12 krev účinky léků MeSH
- recidiva MeSH
- registrace MeSH
- rizikové faktory MeSH
- senioři MeSH
- stenty škodlivé účinky MeSH
- trombocyty účinky léků metabolismus MeSH
- vyšetření funkce trombocytů MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Geografické názvy
- Evropa MeSH
OBJECTIVES: High platelet reactivity (HPR) was studied in patients presenting with ST-segment elevation myocardial infarction (STEMI) due to stent thrombosis (ST) undergoing immediate percutaneous coronary intervention (PCI). BACKGROUND: HPR on P2Y12 inhibitors (HPR-ADP) is frequently observed in stable patients who have experienced ST. The HPR rates in patients presenting with ST for immediate PCI are unknown. METHODS: Consecutive patients presenting with definite ST were included in a multicenter ST registry. Platelet reactivity was measured before immediate PCI with the VerifyNow P2Y12 or Aspirin assay. RESULTS: Platelet reactivity was measured in 129 ST patients presenting with STEMI undergoing immediate PCI. HPR-ADP was observed in 76% of the patients, and HPR on aspirin (HPR-AA) was observed in 13% of the patients. HPR rates were similar in patients who were on maintenance P2Y12 inhibitor or aspirin since stent placement versus those without these medications. In addition, HPR-ADP was similar in patients loaded with a P2Y12 inhibitor shortly before immediate PCI versus those who were not. In contrast, HPR-AA trended to be lower in patients loaded with aspirin as compared with those not loaded. CONCLUSIONS: Approximately 3 out of 4 ST patients with STEMI undergoing immediate PCI had HPR-ADP, and 13% had HPR-AA. Whether patients were on maintenance antiplatelet therapy while developing ST or loaded with P2Y12 inhibitors shortly before undergoing immediate PCI had no influence on the HPR rates. This raises concerns that the majority of patients with ST have suboptimal platelet inhibition undergoing immediate PCI.
2nd Department of Cardiology University Hospital Krakow Poland
Amsterdam Medical Centre Department of Cardiology Amsterdam the Netherlands
Cardiac Department Hospital Universitario de La Princesa Madrid Spain
Coronary Research Group University Hospital Southampton Southampton United Kingdom
Department of Cardiology and Angiology 2 Universitäts Herzzentrum Freiburg Bad Krozingen Germany
Department of Cardiology St Antonius Hospital Nieuwegein the Netherlands
Department of Cardiology Ziekenhuis Oost Limburg Genk Belgium
Deutsches Herzzentrum München Technische Universität München Munich Germany
DZHK partner site Munich Heart Alliance Munich Germany
Institute of Cardiology Jagiellonian University Medical College Kraków Poland
Interventional Cardiology Division Azienda Ospedaliera Papa Giovanni XXIII Bergamo Italy
Medizinische Klinik und Poliklinik 1 Ludwig Maximilians Universität Munich Germany
National Heart and Lung Institute Royal Brompton Hospital Imperial College London United Kingdom
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028656
- 003
- CZ-PrNML
- 005
- 20220106083525.0
- 007
- ta
- 008
- 190813s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jcin.2017.09.019 $2 doi
- 035 __
- $a (PubMed)29268884
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Godschalk, Thea C $u Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
- 245 10
- $a Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry / $c TC. Godschalk, RA. Byrne, T. Adriaenssens, N. Malik, LJ. Feldman, G. Guagliumi, F. Alfonso, FJ. Neumann, D. Trenk, M. Joner, C. Schulz, PG. Steg, AH. Goodall, R. Wojdyla, D. Dudek, JJ. Wykrzykowska, O. Hlinomaz, AG. Zaman, N. Curzen, J. Dens, P. Sinnaeve, W. Desmet, AH. Gershlick, A. Kastrati, S. Massberg, JM. Ten Berg, PRESTIGE Investigators,
- 520 9_
- $a OBJECTIVES: High platelet reactivity (HPR) was studied in patients presenting with ST-segment elevation myocardial infarction (STEMI) due to stent thrombosis (ST) undergoing immediate percutaneous coronary intervention (PCI). BACKGROUND: HPR on P2Y12 inhibitors (HPR-ADP) is frequently observed in stable patients who have experienced ST. The HPR rates in patients presenting with ST for immediate PCI are unknown. METHODS: Consecutive patients presenting with definite ST were included in a multicenter ST registry. Platelet reactivity was measured before immediate PCI with the VerifyNow P2Y12 or Aspirin assay. RESULTS: Platelet reactivity was measured in 129 ST patients presenting with STEMI undergoing immediate PCI. HPR-ADP was observed in 76% of the patients, and HPR on aspirin (HPR-AA) was observed in 13% of the patients. HPR rates were similar in patients who were on maintenance P2Y12 inhibitor or aspirin since stent placement versus those without these medications. In addition, HPR-ADP was similar in patients loaded with a P2Y12 inhibitor shortly before immediate PCI versus those who were not. In contrast, HPR-AA trended to be lower in patients loaded with aspirin as compared with those not loaded. CONCLUSIONS: Approximately 3 out of 4 ST patients with STEMI undergoing immediate PCI had HPR-ADP, and 13% had HPR-AA. Whether patients were on maintenance antiplatelet therapy while developing ST or loaded with P2Y12 inhibitors shortly before undergoing immediate PCI had no influence on the HPR rates. This raises concerns that the majority of patients with ST have suboptimal platelet inhibition undergoing immediate PCI.
- 650 _2
- $a adenosindifosfát $x krev $7 D000244
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a trombocyty $x účinky léků $x metabolismus $7 D001792
- 650 _2
- $a koronární trombóza $x krev $x diagnostické zobrazování $x etiologie $x prevence a kontrola $7 D003328
- 650 _2
- $a léková rezistence $7 D004351
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a koronární angioplastika $x škodlivé účinky $x přístrojové vybavení $7 D062645
- 650 _2
- $a inhibitory agregace trombocytů $x škodlivé účinky $x terapeutické užití $7 D010975
- 650 _2
- $a vyšetření funkce trombocytů $7 D010979
- 650 _2
- $a antagonisté purinergních receptorů P2Y $x škodlivé účinky $x terapeutické užití $7 D058921
- 650 _2
- $a purinergní receptory P2Y12 $x krev $x účinky léků $7 D058925
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a infarkt myokardu s elevacemi ST úseků $x krev $x diagnostické zobrazování $x etiologie $x chirurgie $7 D000072657
- 650 _2
- $a stenty $x škodlivé účinky $7 D015607
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Byrne, Robert A $u Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
- 700 1_
- $a Adriaenssens, Tom $u Department of Cardiology, University Hospitals Leuven and Department of Cardiovascular Sciences, KU Leuven, Belgium.
- 700 1_
- $a Malik, Nikesh $u Department of Cardiovascular Sciences, University of Leicester and NIHR Cardiovascular Biomedical Research Centre, University Hospitals of Leicester, Leicester, United Kingdom.
- 700 1_
- $a Feldman, Laurent J $u French Alliance for Cardiovascular Trials (FACT), DHU FIRE, INSERM, U-1148, Hôpital Bichat, AP-HP, and Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France.
- 700 1_
- $a Guagliumi, Giulio $u Interventional Cardiology Division, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
- 700 1_
- $a Alfonso, Fernando $u Cardiac Department, Hospital Universitario de La Princesa, Madrid, Spain.
- 700 1_
- $a Neumann, Franz-Josef $u Department of Cardiology & Angiology II, Universitäts-Herzzentrum Freiburg Bad Krozingen, Germany.
- 700 1_
- $a Trenk, Dietmar $u Department of Cardiology & Angiology II, Universitäts-Herzzentrum Freiburg Bad Krozingen, Germany.
- 700 1_
- $a Joner, Michael $u Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
- 700 1_
- $a Schulz, Christian $u DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany; Medizinische Klinik und Poliklinik I, Ludwig-Maximilians-Universität, Munich, Germany.
- 700 1_
- $a Steg, Philippe G $u French Alliance for Cardiovascular Trials (FACT), DHU FIRE, INSERM, U-1148, Hôpital Bichat, AP-HP, and Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France; National Heart and Lung Institute, Royal Brompton Hospital, Imperial College, London, United Kingdom.
- 700 1_
- $a Goodall, Alison H $u Department of Cardiovascular Sciences, University of Leicester and NIHR Cardiovascular Biomedical Research Centre, University Hospitals of Leicester, Leicester, United Kingdom.
- 700 1_
- $a Wojdyla, Roman $u 2nd Department of Cardiology, University Hospital, Krakow, Poland.
- 700 1_
- $a Dudek, Dariusz $u Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland.
- 700 1_
- $a Wykrzykowska, Joanna J $u Amsterdam Medical Centre, Department of Cardiology, Amsterdam, the Netherlands.
- 700 1_
- $a Hlinomaz, Ota $u Department of Cardiology, International Clinical Research Center, St Anne Hospital and Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Zaman, Azfar G $u Freeman Hospital and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
- 700 1_
- $a Curzen, Nick $u Coronary Research Group, University Hospital Southampton, Southampton, United Kingdom.
- 700 1_
- $a Dens, Jo $u Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.
- 700 1_
- $a Sinnaeve, Peter $u Department of Cardiology, University Hospitals Leuven and Department of Cardiovascular Sciences, KU Leuven, Belgium.
- 700 1_
- $a Desmet, Walter $u Department of Cardiology, University Hospitals Leuven and Department of Cardiovascular Sciences, KU Leuven, Belgium.
- 700 1_
- $a Gershlick, A. H., $u Department of Cardiovascular Sciences, University of Leicester and NIHR Cardiovascular Biomedical Research Centre, University Hospitals of Leicester, Leicester, United Kingdom. $d 1951-2020 $7 xx0268075
- 700 1_
- $a Kastrati, Adnan $u Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
- 700 1_
- $a Massberg, Steffen $u DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany; Medizinische Klinik und Poliklinik I, Ludwig-Maximilians-Universität, Munich, Germany. Electronic address: steffen.massberg@med.uni-muenchen.de.
- 700 1_
- $a Ten Berg, Jurriën M $u Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands. Electronic address: jurtenberg@gmail.com.
- 710 2_
- $a PRESTIGE Investigators
- 773 0_
- $w MED00186218 $t JACC. Cardiovascular interventions $x 1876-7605 $g Roč. 10, č. 24 (2017), s. 2548-2556
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29268884 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20220106083522 $b ABA008
- 999 __
- $a ok $b bmc $g 1433805 $s 1067116
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 10 $c 24 $d 2548-2556 $e 20171226 $i 1876-7605 $m JACC. Cardiovascular interventions $n JACC Cardiovasc Interv $x MED00186218
- LZP __
- $a Pubmed-20190813
